Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients

Approval of nusinersen, an intrathecally administered antisense oligonucleotide, for the treatment of 5q-spinal muscular atrophy (SMA) marked the beginning of a new therapeutic era in neurological diseases. Changes in routine cerebrospinal fluid (CSF) parameters under nusinersen have only recently b...

Descripción completa

Detalles Bibliográficos
Autores principales: Müschen, Lars Hendrik, Osmanovic, Alma, Binz, Camilla, Jendretzky, Konstantin F., Ranxha, Gresa, Bronzlik, Paul, Abu-Fares, Omar, Wiehler, Flavia, Möhn, Nora, Hümmert, Martin W., Gingele, Stefan, Götz, Friedrich, Stangel, Martin, Skripuletz, Thomas, Schreiber-Katz, Olivia, Petri, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996901/
https://www.ncbi.nlm.nih.gov/pubmed/33652830
http://dx.doi.org/10.3390/brainsci11030296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996901/
https://www.ncbi.nlm.nih.gov/pubmed/33652830
http://dx.doi.org/10.3390/brainsci11030296

Ejemplares similares